Clinical Value of Molecular Genetic Analyzes in Gynecological Malignomas
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- Influence of molecular genetic findings to the therapy decision
Study Overview
Brief Summary
The aim of the planned research project is to find out the clinical significance of molecular genetic analyzes in gynecological malignomas. In particular, it will be investigated how the knowledge of a molecular-genetic finding affects the therapeutic decision of the physician. Furthermore, genetic changes in the tumor tissue will be compared with the changes in CTCs, DTCs and cfDNA.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with a solid tumor disease
- •The presence of a molecular genetic diagnosis of the tumor tissue from practice for human genetics
- •Age > 18 years
- •informed consent
Exclusion Criteria
- •life expectancy <12 months or worse general condition (Karnofsky <70)
Outcomes
Primary Outcomes
Influence of molecular genetic findings to the therapy decision
Time Frame: 3years
It will be analyzed if the physicians selection of a therapy is influenced by a present molecular genetic finding. Therapy recommondation based on molecular genetic analysis will be compared with the acutal therapy decision.
Secondary Outcomes
No secondary outcomes reported
